Jack W. Lawler

Q: What Schools Are Affiliated With Jack W. Lawler

Jack W. Lawler is affiliated with the following schools: Tufts University, University of California, Los Angeles, University of Toronto, Massachusetts General Hospital, Harvard University

Jack W. Lawler's AcademicInfluence.com Rankings

Jack W. Lawler

Biology

#8907

World Rank

#12047

Historical Rank

Neuroscience

#1274

World Rank

#1319

Historical Rank

biology Degrees

Download Badge

Biology

Jack W. Lawler's Degrees

PhD Neurobiology University of California, Irvine
Bachelors Biology University of California, Irvine

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Jack W. Lawler Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jack W. Lawler's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Thrombospondins Are Astrocyte-Secreted Proteins that Promote CNS Synaptogenesis (2005) (1491)
Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo (1998) (1062)
Gabapentin Receptor α2δ-1 Is a Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis (2009) (660)
Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth (2002) (535)
The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins (1986) (512)
Thrombospondin-1 is a major activator of TGF-beta1 in vivo. (1998) (508)
The thrombospondins. (2011) (494)
CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes (1989) (479)
Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor (2001) (462)
Gabapentin Receptor alpha 2 delta-1 Is a Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis (2009) (455)
Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors (1988) (455)
The functions of thrombospondin-1 and-2. (2000) (447)
Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. (1998) (445)
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy (2003) (413)
Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. (2012) (395)
Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. (1978) (381)
The cell biology of thrombospondin-1. (2000) (373)
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. (2005) (360)
Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia (1995) (359)
The structural and functional properties of thrombospondin. (1986) (338)
Integrins as dynamic regulators of vascular function (1994) (304)
Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. (1999) (300)
Critical Role of Endogenous Thrombospondin-1 in Preventing Expansion of Healing Myocardial Infarcts (2005) (292)
The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. (2002) (280)
Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. (1999) (277)
The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. (1994) (253)
Thrombospondins in cancer. (2008) (246)
Crystal structure of the TSP-1 type 1 repeats (2002) (237)
Regulation of tumor angiogenesis by thrombospondin-1. (2006) (228)
C-Mannosylation and O-Fucosylation of the Thrombospondin Type 1 Module* (2001) (222)
Tumor progression: the effects of thrombospondin-1 and -2. (2004) (209)
Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression (2004) (196)
The structure of human platelet thrombospondin. (1985) (196)
A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. (1998) (189)
Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. (2005) (186)
A Thrombospondin-Dependent Pathway for a Protective ER Stress Response (2012) (175)
Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. (2004) (174)
Thrombospondin‐1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor‐related protein‐1 (LRP‐1) (2007) (169)
Characterization of human and mouse cartilage oligomeric matrix protein. (1994) (167)
Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. (2006) (160)
Thrombospondins: from structure to therapeutics (2008) (160)
B-RafV600E and thrombospondin-1 promote thyroid cancer progression (2010) (159)
Structures of thrombospondins. (2008) (151)
cDNA sequence for human erythrocyte ankyrin. (1990) (150)
Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family (1993) (143)
Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes (2011) (141)
An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin [see comments] (1989) (140)
Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by β1 integrins (2005) (135)
Thrombospondin‐1–deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia‐mediated vessel obliteration (2003) (130)
Thrombospondin-based antiangiogenic therapy. (2007) (130)
Cartilage Oligomeric Matrix Protein/Thrombospondin 5 Supports Chondrocyte Attachment through Interaction with Integrins* (2005) (130)
Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. (2001) (126)
Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. (2001) (123)
Interaction of Cartilage Oligomeric Matrix Protein/Thrombospondin 5 with Aggrecan* (2007) (122)
The thrombospondin family (1993) (120)
The effect of thrombospondin-1 on breast cancer metastasis (2009) (118)
Characterization of cartilage oligomeric matrix protein (COMP) in human normal and pseudoachondroplasia musculoskeletal tissues. (1998) (115)
Cartilage Oligomeric Matrix Protein (Thrombospondin-5) Is Expressed by Human Vascular Smooth Muscle Cells (2001) (113)
Cartilage Oligomeric Matrix Protein Is a Calcium-binding Protein, and a Mutation in Its Type 3 Repeats Causes Conformational Changes* (2000) (111)
Evidence for calcium-sensitive structure in platelet thrombospondin. Isolation and partial characterization of thrombospondin in the presence of calcium. (1982) (107)
Thrombospondin‐1 modulates vascular endothelial growth factor activity at the receptor level (2009) (104)
Thrombospondin interactions with fibronectin and fibrinogen. Mutual inhibition in binding. (1984) (104)
Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries. (1998) (103)
Thrombospondin-1 Is an Endogenous Activator of TGF-β in Experimental Diabetic Nephropathy In Vivo (2007) (101)
CD36 associates with CD9 and integrins on human blood platelets. (2001) (100)
An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin. (1989) (98)
The interaction of Thrombospondins with extracellular matrix proteins (2009) (97)
Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer (2011) (94)
Retention of cartilage oligomeric matrix protein (COMP) and cell death in redifferentiated pseudoachondroplasia chondrocytes. (1998) (92)
The release of heparin binding peptides from platelet thrombospondin by proteolytic action of thrombin, plasmin and trypsin. (1981) (91)
The Thrombospondin Gene Family (1995) (88)
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. (2011) (87)
Identification of the protein 4.1 binding site to phosphatidylserine vesicles. (1988) (87)
Cooperative binding of calcium to thrombospondin. The effect of calcium on the circular dichroism and limited tryptic digestion of thrombospondin. (1983) (86)
Characterization of Human Thrombospondin-4 (*) (1995) (84)
Specificity in the interactions of extracellular matrix proteins with subpopulations of the glycosaminoglycan heparin. (1993) (83)
The structures of the thrombospondin-1 N-terminal domain and its complex with a synthetic pentameric heparin. (2006) (82)
Diverse mechanisms for cell attachment to platelet thrombospondin. (1993) (81)
Physical characterization of platelet thrombospondin. (1981) (81)
Skeletal abnormalities in mice lacking extracellular matrix proteins, thrombospondin-1, thrombospondin-3, thrombospondin-5, and type IX collagen. (2008) (80)
Cell-type specific adhesive interactions of skeletal myoblasts with thrombospondin-1. (1994) (80)
Identification of Novel β1 Integrin Binding Sites in the Type 1 and Type 2 Repeats of Thrombospondin-1* (2004) (79)
The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. (2013) (78)
SCFβ-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2 (2012) (78)
Complete amino acid sequence and homologies of human erythrocyte membrane protein band 4.2. (1990) (77)
Muskelin, a novel intracellular mediator of cell adhesive and cytoskeletal responses to thrombospondin‐1 (1998) (77)
Colocalization of thrombospondin and syndecan during murine development (1992) (75)
Thrombospondin-1: An Islet Endothelial Cell Signal of Importance for β-Cell Function (2011) (72)
Partial ankyrin and spectrin deficiency in severe, atypical hereditary spherocytosis. (1988) (72)
A novel orthotopic mouse model of human anaplastic thyroid carcinoma. (2009) (70)
Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations (2017) (70)
Molecular defect of spectrin in hereditary pyropoikilocytosis. Alterations in the trypsin-resistant domain involved in spectrin self-association. (1982) (68)
Hemin-mediated dissociation of erythrocyte membrane skeletal proteins. (1985) (67)
ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer (2009) (67)
Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells. (2005) (67)
Decorin inhibits cell attachment to thrombospondin‐1 by binding to a KKTR‐dependent cell adhesive site present within the N‐terminal domain of thrombospondin‐1 (1997) (65)
Characterization of integrin β6 and thrombospondin‐1 double‐null mice (2005) (65)
Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase. (2011) (64)
Thrombospondin 3 is a developmentally regulated heparin binding protein. (1994) (64)
Integration of pro- and anti-angiogenic signals by endothelial cells (2018) (63)
Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. (2004) (63)
Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model. (2003) (63)
The thrombospondins. (2004) (61)
Role of Thrombospondin-1 in Control of von Willebrand Factor Multimer Size in Mice* (2004) (61)
The crystal structure of the signature domain of cartilage oligomeric matrix protein: implications for collagen, glycosaminoglycan and integrin binding (2009) (60)
A molecular defect of spectrin in a subset of patients with hereditary elliptocytosis. Alterations in the alpha-subunit domain involved in spectrin self-association. (1984) (60)
Molecular requirements for the interaction of thrombospondin with thrombin-activated human platelets: modulation of platelet aggregation. (1992) (59)
Internalization but not binding of thrombospondin‐1 to low density lipoprotein receptor‐related protein‐1 requires heparan sulfate proteoglycans (2004) (59)
Molecular determinants of clinical expression of hereditary elliptocytosis and pyropoikilocytosis. (1987) (59)
Improved Vascular Engraftment and Graft Function After Inhibition of the Angiostatic Factor Thrombospondin-1 in Mouse Pancreatic Islets (2008) (59)
Thrombospondin‐4 is expressed by early osteogenic tissues in the chick embryo (1995) (59)
Cooperation between Thrombospondin-1 Type 1 Repeat Peptides and αvβ3 Integrin Ligands to Promote Melanoma Cell Spreading and Focal Adhesion Kinase Phosphorylation* (1999) (57)
The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. (2006) (57)
Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. (2009) (56)
Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. (2005) (55)
Expression and mutagenesis of thrombospondin. (1992) (54)
Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner (2011) (54)
Thrombospondin 1 and Its Mimetic Peptide ABT-510 Decrease Angiogenesis and Inflammation in a Murine Model of Inflammatory Bowel Disease (2008) (53)
Effect of cartilage oligomeric matrix protein on mesenchymal chondrogenesis in vitro. (2003) (52)
Structural and functional heterogeneity of alpha spectrin mutations involving the spectrin heterodimer self-association site: relationships to hematologic expression of homozygous hereditary elliptocytosis and hereditary pyropoikilocytosis. (1990) (52)
Thrombospondin-1 plays a critical role in the induction of hair follicle involution and vascular regression during the catagen phase. (2003) (52)
Inhibition of Tie-2 Signaling Induces Endothelial Cell Apoptosis, Decreases Akt Signaling and Induces Endothelial Cell Expression of the Endogenous Anti-Angiogenic Molecule, Thrombospondin-1 (2004) (51)
Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1. (1998) (51)
A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. (2009) (50)
Activation of Platelet-transforming Growth Factor β-1 in the Absence of Thrombospondin-1* (2000) (49)
Thrombin and Chymotrypsin Interactions with Thrombospondin a (1986) (48)
In situ localization of thrombospondin‐1 and thrombospondin‐3 transcripts in the avian embryo (1997) (47)
Combined therapy with thrombospondin‐1 type I repeats (3TSR) and chemotherapy induces regression and significandy improves survival in a preclinical model of advanced stage epithelial ovarian cancer (2015) (46)
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? (2010) (44)
Inhibition of sickle erythrocyte adhesion to immobilized thrombospondin by von Willebrand factor under dynamic flow conditions. (1997) (42)
Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts. (1996) (41)
Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas. (2015) (41)
Adeno-Associated Virus–Mediated Antiangiogenic Gene Therapy with Thrombospondin-1 Type 1 Repeats and Endostatin (2007) (41)
Proteolysis of thrombospondin during cathepsin‐G‐induced platelet aggregation: functional role of the 165‐kDa carboxy‐terminal fragment (1996) (39)
Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer (2018) (39)
Thrombospondin 3 Is a Pentameric Molecule Held Together by Interchain Disulfide Linkage Involving Two Cysteine Residues (*) (1995) (38)
Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis (2018) (35)
Cloning and sequencing of chicken thrombospondin. (1991) (35)
Thrombospondin‐1 and neural crest cell migration (1999) (34)
Antiangiogenic Treatment with Three Thrombospondin-1 Type 1 Repeats versus Gemcitabine in an Orthotopic Human Pancreatic Cancer Model (2005) (34)
The C-terminal domain of thrombospondin-1 induces vascular smooth muscle cell chemotaxis. (2001) (33)
Heparin-induced cis- and trans-Dimerization Modes of the Thrombospondin-1 N-terminal Domain* (2008) (33)
Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1. (1997) (32)
Characterization of the murine thrombospondin gene. (1991) (31)
Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism (2006) (31)
Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment. (2014) (31)
Plasmodium falciparum-infected erythrocyte adhesion to the type 3 repeat domain of thrombospondin-1 is mediated by a modified band 3 protein. (1999) (30)
Thrombospondin-1-deficient mice are not protected from bleomycin-induced pulmonary fibrosis. (2011) (30)
The angiogenesis inhibitor thrombospondin-1 inhibits acute cutaneous hypersensitivity reactions. (2009) (30)
Thrombospondins in early Xenopus embryos: Dynamic patterns of expression suggest diverse roles in nervous system, notochord, and muscle development (1998) (30)
Antiangiogenic Treatment with the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein in an Orthotopic Human Pancreatic Cancer Model (2005) (29)
The evolution of the thrombospondin gene family (1993) (29)
Latency Associated Peptide Has In Vitro and In Vivo Immune Effects Independent of TGF-β1 (2008) (28)
Members of the thrombospondin gene family bind stromal interaction molecule 1 and regulate calcium channel activity (2014) (28)
Sp alpha I/65: a new variant of the alpha subunit of spectrin in hereditary elliptocytosis. (1985) (27)
Activation of Latent TGF-β1 by Thrombospondin-1 is a Major Component of Wound Repair. (2005) (27)
Molecular heterogeneity of hereditary pyropoikilocytosis: identification of a second variant of the spectrin alpha-subunit. (1983) (26)
Structural organization of the thrombospondin molecule. (1987) (25)
Effects of heat shock on the expression of thrombospondin by endothelial cells in culture (1988) (24)
Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. (2007) (23)
Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake (2021) (23)
Thrombospondin-1 Interacts with Trypanosoma cruzi Surface Calreticulin to Enhance Cellular Infection (2012) (22)
Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAFV600E: New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment (2013) (22)
Cooperation between thrombospondin-1 type 1 repeat peptides and alpha(v)beta(3) integrin ligands to promote melanoma cell spreading and focal adhesion kinase phosphorylation. (1999) (22)
Prediction of the secondary structure of platelet factor 4 and beta-thromboglobulin from their amino acid sequences. (1981) (21)
Molecular heterogeneity of hereditary pyropoikilocytosis: identification of a second variant of the spectrin alpha-subunit (1983) (20)
Observation of a High Molecular Weight Platelet Protein Released by Thrombin (1977) (20)
Structural and immunological comparison of human thrombospondins isolated from platelets and from culture supernatants of endothelial cells and fibroblasts. Evidence for a thrombospondin polymorphism. (1986) (20)
Thrombospondin‐1‐induced vascular smooth muscle cell chemotaxis: The role of the type 3 repeat and carboxyl terminal domains (2003) (20)
Cartilage Oligomeric Matrix Protein (2002) (19)
Heparin‐binding domain, type 1 and type 2 repeats of thrombospondin mediate its interaction with human breast cancer cells (1996) (19)
Residues F16-G33 and A784-N823 within platelet thrombospondin-1 play a major role in binding human neutrophils: evaluation by two novel binding assays. (2000) (19)
Thrombospondins: from structure to therapeutics (2008) (19)
Masking epistasis between MYC and TGF-β pathways in antiangiogenesis-mediated colon cancer suppression. (2014) (18)
The crystal structure of the heparin-binding reelin-N domain of f-spondin. (2008) (18)
Thrombospondin-1 in a Murine Model of Colorectal Carcinogenesis (2015) (18)
The thrombospondin-4 gene (1999) (18)
Thrombospondin in essential thrombocythemia. (1986) (17)
CD36 mediates binding of soluble thrombospondin‐1 but not cell adhesion and haptotaxis on immobilized thrombospondin‐1 (1998) (17)
Extracellular matrix: the thrombospondin family. (1993) (15)
Localization of thrombospondin, CD36 and CD51 during prenatal development of the human mammary gland. (1994) (15)
CD 36 associates with CD 9 and integrins on human blood platelets (2001) (15)
Effects of thrombospondin antibody on the recovery of endothelial cells from hyperthermia. (1990) (14)
Platelet antithrombin defect in malignancy: platelet protein alterations. (1987) (14)
Aggregation of Platelets and Inert Particles Induced by Thrombin (1976) (13)
Clinical and laboratory study of two Caucasian families with hereditary pyropoikilocytosis and hereditary elliptocytosis. (1987) (12)
Sp all65: A New Variant of the a Subunit of Spectrin in Hereditary Elliptocytosis (1985) (12)
Falciparum malaria parasitized erythrocytes bind to a carboxy-terminal thrombospondin fragment and not the amino-terminal heparin-binding region. (1990) (12)
Introduction to the Tumour Microenvironment Review Series (2009) (11)
Vascular response to intra-arterial injury in the thrombospondin-1 null mouse. (2007) (11)
Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro (2014) (11)
Role of Thrombospondin-1 in the Autologous Phase of an Accelerated Model of Anti-Glomerular Basement Membrane Glomerulonephritis (2004) (10)
Spectrin-alpha I/61: a new structural variant of alpha-spectrin in a double-heterozygous form of hereditary pyropoikilocytosis. (1988) (9)
Severe hemolysis and red cell fragmentation caused by the combination of a spectrin mutation with a thrombotic microangiopathy (1989) (9)
The structure of the Ca2+-binding, glycosylated F-spondin domain of F-spondin - A C2-domain variant in an extracellular matrix protein (2011) (9)
Thrombospondin-1-Based Antiangiogenic Therapy. (2015) (8)
Endothelial Cell Behavior Is Determined by Receptor Clustering Induced by Thrombospondin-1 (2021) (7)
The effect of ultraviolet light on platelets: platelet activation and inhibition of thrombin-mediated functions. (1979) (7)
Vascular smooth muscle cell migration induced by domains of thrombospondin-1 is differentially regulated. (2011) (7)
Fluvastatin inhibits intimal hyperplasia in wild-type but not Thbs1-null mice. (2017) (5)
Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer. (2021) (5)
Production, characterization, and use of monoclonal antibodies directed against human blood platelet thrombospondin: immunologic comparison with human endothelial and fibroblast thrombospondins. (1987) (4)
Extracellular matrix components affect the pattern of protein synthesis of endothelial cells responding to hyperthermia (1993) (4)
AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinoma (2019) (4)
Megakaryocytes join the war on cancer. (2010) (3)
Purification and Analysis of Thrombospondin‐1 (2003) (3)
Thrombospondin in essential thrombocythemia (1986) (3)
Editorial [Hot topic: Thrombospondins (Guest Editor: Jack Lawler)] (2008) (3)
Pro‐Resolving Lipid Mediators and Anti‐Angiogenic Therapy Exhibit Synergistic Anti‐Tumor Activity via Resolvin Receptor Activation (2020) (3)
Counter Regulation of Tumor Angiogenesis by Vascular Endothelial Growth Factor and Thrombospondin-1. (2022) (2)
IDENTIFICATION OF A NEW STRUCTURAL VARIANT OF α SPECTRIN IN A DOUBLE HETEROZYGOUS FORM OF HEREDITARY PYROPOIKILOCYTOSIS (HPP) (1987) (2)
Basic and clinical research on angiogenesis (1996) (2)
Program and abstracts for the 2012 Joint Meeting of the Society for Glycobiology & American Society for Matrix Biology (2012) (2)
Discoveries: an innovative platform for publishing cutting-edge research discoveries in medicine, biology and chemistry (2013) (2)
Erratum to Effect of cartilage oligomeric matrix protein on mesenchymal chondrogenesis in vitro [Osteoarthritis Cartilage 11 (6) (2003) 442–454] (2003) (1)
Comparison of antiangiogenic therapy with thrombospondin type I repeats and gemcitabine in an orthotopic model of pancreatic cancer in SCID mice (2004) (1)
Anti-angiogenic Therapy and Induction of Blood Vessel Normalization in the Treatment of Ovarian Cancer (2014) (1)
Anti-Angiogenic Therapy with Thrombospondins (2008) (1)
Crystal Structure of the Thrombospondin-1 Type 1 Repeats (2002) (0)
The Thrombospondin-1 N700S Polymorphism Does Not Alter von Willebrand Factor Multimer Size in Patients Suffering an Acute Myocardial Infarction. (2005) (0)
Comparison of thrombospondin-1 type I repeats anti-angiogenic therapy with gemcitabine in an orthotopic pancreatic cancer model (2005) (0)
The Effect of 3TSR on Corneal Hem- and Lymphoangiogenesis (2007) (0)
aggregation thrombin-activated human platelets: modulation of platelet Molecular requirements for the interaction of thrombospondin with (2011) (0)
The crystal structure of the Thrombospondin-1 N-terminal domain in complex with fractionated Heparin DP8 (2008) (0)
Human and murine data suggest critical role for TGF-β in the aetiopathogenesis of Barrett's oesophagus (2001) (0)
Original Paper Tumour Suppressor Genes and Angiogenesis: the Role of 7P53 in Fibroblasts (1996) (0)
Thrombospondin‐1 binding protein on the surface of Trypanosoma cruzi enhances cellular infection (2012) (0)
Integration of pro- and anti-angiogenic signals by endothelial cells (2017) (0)
Thrombospondin 1 gene deficiency modulates vascular medial smooth muscle cell activation and neointima formation (2007) (0)
When is a thrombogenic matrix not thrombogenic? (2016) (0)
Three new variants of the alpha1-globin gene without clinical or hematologic effects: Hb Hagerstown [alpha44(CE2)Pro-->Ala (alpha1)]; Hb Buffalo [alpha89(FG1)His-->Gln (alpha1)], a hemoglobin variant from Somalia and Yemen; Hb Wichita [alpha95(G2)Pro-->Gln (alpha1)]; and a second, unrelated, case of (2002) (0)
Endothelial Biomedicine: Thrombospondins (2007) (0)
Dosage de diagnostic pour la thrombocytopenie induite par l'heparine de type 2 (2000) (0)
Exogeneous Thrombospondin 1 Inhibits Inflammatory Corneal Lymphangiogenesis in-vivo (2011) (0)
A Complex Glycoprotein Released from Platelets by Thrombin Action (1977) (0)
Regulation of Angiogenesis and Tumor Growth by Thrombospondin-1 (2008) (0)
Factors Influencing Thrombin Digestion Of Human Platelet Thrombospondin (1981) (0)
Factor Thrombospondin-1 in Mouse Pancreatic Islets Improved Vascular Engraftment and Graft Function (2003) (0)
AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinoma (2019) (0)
Role of thrombospondin-1 in a mouse model of breast cancer (2005) (0)
Crystal Structure of Thrombospondin-1 N-terminal Domain in P1 Form at 1.85A Resolution (2006) (0)
Vascular Smooth Muscle Cells Cartilage Oligomeric Matrix Protein ( Thrombospondin-5 ) Is Expressed (2000) (0)
Crystal Structure of the Thrombospondin-1 N-terminal domain (2006) (0)
TRAIL Induced Apoptosis is Enhanced by Inhibition of the MAPK and PI3K/AKT Pathways in Thyroid Cancer Cells (2013) (0)
Thrombospondin 1 Is an Endogenous Inhibitor of Inflammatory Lymphangiogenesis and Maintains Corneal Lymphangiogenic Privilege (2007) (0)
Induction of Thrombospondin (TSP)‐1 and Tissue Transglutaminase (tTG) in the Infarct Border Zone May Limit Expansion of Granulation Tissue Formation (2006) (0)
Abstract 1042: Fc3TSR improves intratumoral treatment delivery by normalizing tumor vasculature and reducing interstitial fluid pressure in an orthotopic, syngeneic mouse model of epithelial ovarian cancer (2022) (0)
Investigating an orally available small-molecule inhibitor (vemurafenib) of BRAFV600E in a novel preclinical model of human papillary thyroid cancer. (2013) (0)
Corrigendum: Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells With BRAFV600E: New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment (2020) (0)
Crystal Structure of the Thrombospondin-1 N-terminal Domain at 1.45A Resolution (2006) (0)
Thrombospondin-1 secures thrombus adherence in vivo by protecting (sub)endothelial VWF from leavage by ADAMTS13 (2005) (0)
The crystal structure of the signature domain of cartilage oligomeric matrix protein. (2009) (0)
Abnormalities in spectrin structure and function in hereditary pyropoikilocytosis and hereditary elliptocytosis. (1984) (0)
IMPROVED VASCULAR ENGRAFTMENT AND GRAFT FUNCTION FOLLOWING INHIBITION OF THE ANGIOSTATIC FACTOR THROMBOSPONDIN-1 IN MOUSE PANCREATIC ISLETS (2008) (0)
Thrombospondin-1 null mice manifest defective platelet recruitment on activated endothelium and reduced thrombus anchoring on damaged vessel walls (2003) (0)
Correction (2005) (0)
Abstract 280: Thrombospondin-1 Carries CD55 like Domains: A Novel Target for E. coli Invasion into Human Heart Cells (2014) (0)
Thrombospondin-1 gene deficiency attenuates atherosclerotic plaque burden but accentuates inflammatory cell plaque content in ApoE-deficient mice (2007) (0)
Treating high-grade glioma with oncolytic virotherapy and histone deacetylase inhibitors (0)
Thrombospondin-1 as a Modulator of ADAMTS13 Activity. (2007) (0)
Crystal Structure of the Thrombospondin-1 N-terminal Domain in Complex with Arixtra (2006) (0)
Skeletal abnormalities in quad-KO mice (TSP1, 3, 5, and Col 9) (2008) (0)
Thrombospondin: Heart shock-stimulated expression by endothelial cells in culture (1987) (0)
myocardial infarction without altering von Willebrand Factor multimer size The thrombospondin-1 N700S polymorphism is associated with early (2013) (0)
1002-78 The critical role of thrombospondin (TSP)-1 in limiting expansion of fibrosis in healing myocardial infarcts: Studies in dogs and TSP-1 -/- mice (2004) (0)
The crystal structure of Reelin-N domain of F-spondin (2008) (0)
elliptocytosis Sp alpha I/65: a new variant of the alpha subunit of spectrin in hereditary (2011) (0)
Proapoptotic and survival signaling pathways plays a role in thrombospondin type I repeat mediated apoptosis in human microvascular endothelial cells (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jack W. Lawler?

Jack W. Lawler is affiliated with the following schools:

Jack W. Lawler's Academic­Influence.com Rankings